Summit Global Investments Purchases 5,220 Shares of AbbVie Inc. $ABBV

Summit Global Investments raised its position in shares of AbbVie Inc. (NYSE:ABBV) by 45.1% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 16,792 shares of the company’s stock after purchasing an additional 5,220 shares during the quarter. Summit Global Investments’ holdings in AbbVie were worth $4,393,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of ABBV. Coyle Financial Counsel LLC boosted its position in shares of AbbVie by 3.1% during the third quarter. Coyle Financial Counsel LLC now owns 8,020 shares of the company’s stock valued at $2,098,000 after buying an additional 240 shares during the last quarter. Sagace Wealth Management LLC bought a new stake in AbbVie in the 3rd quarter worth about $235,000. Americana Partners LLC increased its holdings in AbbVie by 0.5% in the 3rd quarter. Americana Partners LLC now owns 268,612 shares of the company’s stock worth $70,266,000 after buying an additional 1,313 shares in the last quarter. Aprio Wealth Management LLC raised its position in AbbVie by 15.2% in the 3rd quarter. Aprio Wealth Management LLC now owns 12,020 shares of the company’s stock worth $3,144,000 after buying an additional 1,590 shares during the last quarter. Finally, Fusion Capital LLC raised its position in AbbVie by 3.9% in the 3rd quarter. Fusion Capital LLC now owns 37,545 shares of the company’s stock worth $9,821,000 after buying an additional 1,393 shares during the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie Price Performance

Shares of ABBV opened at $294.80 on Friday. AbbVie Inc. has a one year low of $190.75 and a one year high of $298.74. The firm has a market capitalization of $520.85 billion, a P/E ratio of 50.74, a PEG ratio of 1.35 and a beta of 0.24. The business has a fifty day moving average of $269.35 and a 200 day moving average of $237.23.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, October 30th. The company reported $3.82 earnings per share for the quarter, beating analysts’ consensus estimates of $3.73 by $0.09. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The company had revenue of $17.40 billion for the quarter, compared to the consensus estimate of $17.32 billion. During the same quarter in the prior year, the company earned $1.86 earnings per share. AbbVie’s revenue was up 10.3% on a year-over-year basis. Analysts expect that AbbVie Inc. will post 13.92 EPS for the current fiscal year.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie’s dividend payout ratio is currently 195.48%.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. Morgan Stanley upped their target price on shares of AbbVie from $296.00 to $310.00 and gave the company an “overweight” rating in a research note on Wednesday, October 7th. Argus lifted their price target on shares of AbbVie from $250.00 to $270.00 in a research note on Tuesday, August 4th. Piper Sandler boosted their price objective on shares of AbbVie from $298.00 to $303.00 and gave the company an “overweight” rating in a report on Thursday, August 20th. Weiss Ratings upgraded shares of AbbVie from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, October 8th. Finally, Guggenheim restated a “buy” rating and set a $288.00 price objective on shares of AbbVie in a research report on Friday, October 9th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $279.86.

Insider Buying and Selling

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.06% of the company’s stock.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q3 results beat expectations. Adjusted earnings per share were $3.82 versus the $3.73 analyst consensus, while revenue rose 10.3% year over year to $17.404 billion, ahead of the $17.32 billion estimate. Adjusted EPS more than doubled from the prior-year quarter. AbbVie Reports Third-Quarter 2026 Financial Results
• Positive Sentiment: Immunology and neuroscience provided strong momentum. Skyrizi generated $5.776 billion in revenue and Rinvoq produced $2.706 billion, helping immunology revenue increase 16.3%. Neuroscience revenue climbed 19.4%, led by Vraylar, therapeutic Botox, Ubrelvy and Qulipta. AbbVie Lifts 2026 Outlook as Immunology, Neuroscience Quarterly Sales Beat Views
• Positive Sentiment: Management raised guidance and its dividend. AbbVie increased its 2026 adjusted EPS outlook to $13.95–$13.99 from $13.76–$13.96, despite including $0.69 per share of year-to-date acquired in-process research and development and milestone expenses. The company also announced a 5.2% dividend increase beginning with the February 2027 payment. AbbVie Raises FY26 Adjusted EPS Outlook and Boosts Dividend
• Positive Sentiment: Pipeline expansion supports longer-term confidence. AbbVie completed its acquisition of Apogee Therapeutics, strengthening its immunology pipeline, while Qulipta also outperformed topiramate in a Phase 3 migraine-prevention study. AbbVie QULIPTA Phase 3 Migraine Prevention Trial
• Negative Sentiment: Investors remain focused on valuation and concentration risks. Humira revenue fell 31.2% to $683 million, while aesthetics revenue declined 1.4%. After a substantial multiyear rally and trading near its 52-week high, analysts question whether additional valuation expansion is justified and how effectively AbbVie can sustain growth beyond Skyrizi and Rinvoq. Skyrizi and Rinvoq Dominate AbbVie Q3

AbbVie Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.